Skip to main content
. 2017 Oct 26;8(58):97769–97786. doi: 10.18632/oncotarget.22080

Figure 11. Discrepant predictive modeling plots.

Figure 11

Patient A had decreasing CA19-9 and ctDNA KRAS levels as compared to baseline, but a RECIST 1.1 assessment of progressive disease (PD) (A). Patient B had increasing CA19-9 and ctDNA KRAS as compared to baseline, but the difference between the baseline and longitudinal timepoints did not meet threshold for a PD call (B). In Patient C, there was a predicted response of stable disease response, and the longitudinal ctDNA KRAS was just below our threshold, thus this is a borderline case (C).